{"id":67642,"date":"2025-08-15T00:23:08","date_gmt":"2025-08-15T00:23:08","guid":{"rendered":"https:\/\/www.newsbeep.com\/uk\/67642\/"},"modified":"2025-08-15T00:23:08","modified_gmt":"2025-08-15T00:23:08","slug":"eli-lilly-raises-uk-price-of-obesity-drug-by-up-to-170-after-trump-freeloading-gripe","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/uk\/67642\/","title":{"rendered":"Eli Lilly raises UK price of obesity drug by up to 170% after Trump \u2018freeloading\u2019 gripe"},"content":{"rendered":"<p>Unlock the Editor\u2019s Digest for free<\/p>\n<p class=\"article__content-sign-up-topic-description o3-type-body-base\">Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.<\/p>\n<p>Eli Lilly has raised the UK price of its popular weight-loss drug Mounjaro by as much as 170 per cent, as it tries to address complaints by Donald Trump\u2019s administration about \u201cforeign freeloaders\u201d who rely on the US to pay more for medicines.\u00a0<\/p>\n<p>The US pharmaceuticals group said the sharp increase in the UK cost of the shot, also used to treat diabetes, from September would \u201caddress pricing inconsistencies compared with other developed countries, including in Europe\u201d.\u00a0<\/p>\n<p>But <a href=\"https:\/\/www.ft.com\/stream\/b149f4eb-f2bc-4b8b-b915-249b37caaf65\" data-trackable=\"link\" rel=\"nofollow noopener\" target=\"_blank\">Lilly<\/a> said it was not raising the price paid by the NHS, to ensure continued supply of the drug, and that it was working with private healthcare providers to maintain access to a jab recommended to more than 3mn people in England.\u00a0Private providers can agree confidential discounts with the company.<\/p>\n<p>The price for a month\u2019s supply of the highest doses of the drug will rise from \u00a3122 to \u00a3330, an increase of 170 per cent. Prices for lower doses will rise by between 45 per cent and 138 per cent. <\/p>\n<p>The <a href=\"https:\/\/www.ft.com\/pharmaceuticals\" data-trackable=\"link\" rel=\"nofollow noopener\" target=\"_blank\">pharmaceutical industry<\/a> is desperate to see off the threat of Trump\u2019s <a href=\"https:\/\/www.whitehouse.gov\/presidential-actions\/2025\/05\/delivering-most-favored-nation-prescription-drug-pricing-to-american-patients\/\" data-trackable=\"link\" rel=\"nofollow noopener\" target=\"_blank\">\u201cmost favoured nation\u201d<\/a> drug pricing proposal to peg US prices to those abroad. US drug prices are on average almost three times higher than those in many other developed countries, according to research by The Rand Corporation.<\/p>\n<p>The threat of US price cuts has hung over <a href=\"https:\/\/www.ft.com\/drug-prices\" data-trackable=\"link\" rel=\"nofollow noopener\" target=\"_blank\">drug pricing<\/a> negotiations with the NHS, as drugmakers are reluctant to agree to a deal in the UK that could affect the prices they can charge in the US.\u00a0\u00a0<\/p>\n<p>Tense talks about changes to a clawback tax placed on drug sales to limit NHS spending on medicines have dragged on past deadlines to solve the problem.\u00a0<\/p>\n<p>While the UK government\u2019s most recent proposal said it would spend more on drugs, chief executives were disappointed by the lack of detail, with little information about the timeframe for spending more, or whether they would spend more by simply buying more drugs, rather than raising prices, according to one industry insider.\u00a0<\/p>\n<p>Trump has paid particularly close attention to the price difference in obesity drugs. In one speech the US president complained that a friend in London had bought the \u201cfat shot drug\u201d for far less than in the US.\u00a0<\/p>\n<p>Lilly said the UK was one of the first countries where it launched Mounjaro and its priority was to bring supply to diabetes patients as quickly as possible.\u00a0<\/p>\n<p>\u201cAt launch, Lilly agreed to a UK list price that is significantly below the European average to prevent delays in NHS availability. With changes in the environment and new clinical evidence supporting the value of Mounjaro, we are now aligning the list price more consistently to ensure fair global contributions to the cost of innovation,\u201d it said.\u00a0<\/p>\n<p>The National Institute for Health and Care Excellence, which decides which drugs are value for money for the NHS, has recommended that Mounjaro be prescribed for up to a possible 3.4mn people in England. But because this would be hard for the NHS to pay for, it later agreed to a staged rollout, starting with about a quarter of a million people with the highest clinical needs in the first three years.\u00a0<\/p>\n<p>NHS England said the price increase would not affect how it supplied Mounjaro to patients with obesity or diabetes, calling it a cost-effective and \u201cvaluable tool to support people to reach a healthier weight and the wider health and lifestyle benefits that offers\u201d.<\/p>\n<p class=\"n-content-recommended__title o3-type-body-highlight\">Recommended<\/p>\n<p><a href=\"https:\/\/www.ft.com\/content\/2566360d-f451-4f72-89b6-2290a7bf140d\" data-trackable=\"image-link\" data-trackable-context-story-link=\"image-link\" tabindex=\"-1\" aria-hidden=\"true\" rel=\"nofollow noopener\" target=\"_blank\"><img decoding=\"async\" class=\"o-teaser__image\" src=\"https:\/\/www.newsbeep.com\/uk\/wp-content\/uploads\/2025\/08\/https:\/\/www.ft.com\/__origami\/service\/image\/v2\/images\/raw\/https%3A%2F%2Fd1e00ek4ebabms.cloudfront.net.jpeg\" alt=\"A general view of signage at Astra Zeneca\u2019s vaccine plant at Speke\"\/><\/a><\/p>\n<p>Dr Leyla Hannbeck, chief executive of the Independent Pharmacies Association, said the organisation was \u201cshocked and very disappointed\u201d by the \u201chuge\u201d price rise in the drug. \u201cThis is a real blow to patients, at a time when more and more people worried about their weight are turning to jabs.\u201d<\/p>\n<p>She also called on the government to develop \u201ccontingencies\u201d in case there were other price rises. \u201cWe are concerned that more pharmaceutical companies may increase their prices as a result of tariffs and this will have a detrimental impact on our medicines market, our pharmacies and our patients.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"Unlock the Editor\u2019s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this&hellip;\n","protected":false},"author":2,"featured_media":67643,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[43],"tags":[102,2960,56,54,55],"class_list":{"0":"post-67642","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-health","9":"tag-healthcare","10":"tag-uk","11":"tag-united-kingdom","12":"tag-unitedkingdom"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/67642","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/comments?post=67642"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/67642\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media\/67643"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media?parent=67642"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/categories?post=67642"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/tags?post=67642"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}